Advances in virtual screening

Although the term virtual screening as the in silico analog of high throughput screening has been coined only a decade ago, virtual screening is now a widespread lead identification method in the pharmaceutical industry. A myriad of different methods have been developed exploiting the growing library of target structures and assay data as a basis for finding new lead structures. Exploiting synergies between different methods best utilizes the information available and is at the center of recent developments. Section editors: Tudor Oprea – University of New Mexico, School of Medicine, Albuquerque, USA Alex Tropsha – University of North Carolina, Chapel Hill, USA

[1]  Dan C. Fara,et al.  Integration of virtual and physical screening , 2006, Drug Discovery Today: Technologies.

[2]  Andrew Potter,et al.  Identification of chemically diverse Chk1 inhibitors by receptor-based virtual screening. , 2006, Bioorganic & medicinal chemistry.

[3]  Prasad V. Bharatam,et al.  New leads for selective GSK-3 inhibition: pharmacophore mapping and virtual screening studies , 2006, J. Comput. Aided Mol. Des..

[4]  Wolfgang Guba,et al.  Integrating molecular design resources within modern drug discovery research: the Roche experience. , 2006, Drug discovery today.

[5]  Matthias Rarey,et al.  Small Molecule Docking and Scoring , 2001 .

[6]  T. Langer,et al.  Strategies for efficient lead structure discovery from natural products. , 2006, Current medicinal chemistry.

[7]  Dariusz Plewczynski,et al.  Assessing Different Classification Methods for Virtual Screening , 2006, J. Chem. Inf. Model..

[8]  Victor A Kenyon,et al.  Novel human lipoxygenase inhibitors discovered using virtual screening with homology models. , 2006, Journal of medicinal chemistry.

[9]  Robert P Sheridan,et al.  Why do we need so many chemical similarity search methods? , 2002, Drug discovery today.

[10]  Thierry Langer,et al.  The discovery of new 11beta-hydroxysteroid dehydrogenase type 1 inhibitors by common feature pharmacophore modeling and virtual screening. , 2006, Journal of medicinal chemistry.

[11]  Alexander Golbraikh,et al.  Application of predictive QSAR models to database mining: identification and experimental validation of novel anticonvulsant compounds. , 2004, Journal of medicinal chemistry.

[12]  Artem Cherkasov,et al.  Successful in silico discovery of novel nonsteroidal ligands for human sex hormone binding globulin. , 2005, Journal of medicinal chemistry.

[13]  Peter Willett,et al.  Similarity-based virtual screening using 2D fingerprints. , 2006, Drug discovery today.

[14]  Haralambos Sarimveis,et al.  Investigation of substituent effect of 1-(3,3-diphenylpropyl)-piperidinyl phenylacetamides on CCR5 binding affinity using QSAR and virtual screening techniques , 2006, J. Comput. Aided Mol. Des..

[15]  Tudor I. Oprea,et al.  Integration of Virtual Screening with High-Throughput Flow Cytometry to Identify Novel Small Molecule Formylpeptide Receptor Antagonistss⃞ , 2005, Molecular Pharmacology.

[16]  Y. Martin,et al.  Challenges and prospects for computational aids to molecular diversity , 1996 .

[17]  Gisbert Schneider,et al.  Ligand-based combinatorial design of selective purinergic receptor (A2A) antagonists using self-organizing maps. , 2003, Journal of combinatorial chemistry.

[18]  P Willett,et al.  Development and validation of a genetic algorithm for flexible docking. , 1997, Journal of molecular biology.

[19]  Michal Vieth,et al.  SDOCKER: a method utilizing existing X-ray structures to improve docking accuracy. , 2004, Journal of medicinal chemistry.

[20]  G. Schneider,et al.  Extraction and visualization of potential pharmacophore points using support vector machines: application to ligand-based virtual screening for COX-2 inhibitors. , 2005, Journal of medicinal chemistry.

[21]  Yovani Marrero-Ponce,et al.  Ligand-Based Virtual Screening and in Silico Design of New Antimalarial Compounds Using Nonstochastic and Stochastic Total and Atom-Type Quadratic Maps , 2005, J. Chem. Inf. Model..

[22]  Antti Poso,et al.  Virtual screening of novel CB2 ligands using a comparative model of the human cannabinoid CB2 receptor. , 2005, Journal of medicinal chemistry.

[23]  Brian K. Shoichet,et al.  Virtual Screening in Drug Discovery , 2005 .

[24]  A Good,et al.  Structure-based virtual screening protocols. , 2001, Current opinion in drug discovery & development.

[25]  Anil K. Saxena,et al.  Evaluation of Binary QSAR Models Derived from LUDI and MOE Scoring Functions for Structure Based Virtual Screening , 2006, J. Chem. Inf. Model..

[26]  Thy-Hou Lin,et al.  Discovery of a novel family of SARS-CoV protease inhibitors by virtual screening and 3D-QSAR studies. , 2006, Journal of medicinal chemistry.

[27]  Qiang Zhang,et al.  Scaffold hopping through virtual screening using 2D and 3D similarity descriptors: ranking, voting, and consensus scoring. , 2006, Journal of medicinal chemistry.

[28]  Paolo Bonvini,et al.  Identification of ellagic acid as potent inhibitor of protein kinase CK2: a successful example of a virtual screening application. , 2006, Journal of medicinal chemistry.

[29]  Y. Martin,et al.  A general and fast scoring function for protein-ligand interactions: a simplified potential approach. , 1999, Journal of medicinal chemistry.

[30]  Andrew C. Good,et al.  Three‐Dimensional Structure Database Searches , 2007 .

[31]  D. Faller,et al.  Identification of Novel Small‐molecule Inducers of Fetal Hemoglobin Using Pharmacophore and ‘PSEUDO’ Receptor Models , 2006, Chemical biology & drug design.

[32]  Wolfgang Guba,et al.  Focused library design in GPCR projects on the example of 5‐HT2c agonists: Comparison of structure‐based virtual screening with ligand‐based search methods , 2005, Proteins.

[33]  Matthias Rarey,et al.  Feature trees: A new molecular similarity measure based on tree matching , 1998, J. Comput. Aided Mol. Des..

[34]  Tudor I. Oprea,et al.  Virtual and biomolecular screening converge on a selective agonist for GPR30 , 2006, Nature chemical biology.

[35]  Manfred E. Wolff,et al.  Burger's Medicinal chemistry , 1980 .

[36]  Z. Deng,et al.  Bridging chemical and biological space: "target fishing" using 2D and 3D molecular descriptors. , 2006, Journal of medicinal chemistry.

[37]  Mark A. Murcko,et al.  Virtual screening : an overview , 1998 .

[38]  Richard A Ward,et al.  Structure-based virtual screening for low molecular weight chemical starting points for dipeptidyl peptidase IV inhibitors. , 2005, Journal of medicinal chemistry.

[39]  Yvonne C. Martin,et al.  Searching Databases of Three‐Dimensional Structures , 2007 .

[40]  Alexander Tropsha,et al.  Application of validated QSAR models of D1 dopaminergic antagonists for database mining. , 2005, Journal of medicinal chemistry.

[41]  Rick Mullin,et al.  DRUG DISCOVERY: As high-throughput screening draws fire, researchers leverage science to put automation into perspective , 2004 .

[42]  I. Muegge Selection criteria for drug‐like compounds , 2003, Medicinal research reviews.

[43]  山下 伸二,et al.  Virtual Screening を目指した薬物動態研究 , 2002 .

[44]  Brian K. Shoichet,et al.  Virtual screening of chemical libraries , 2004, Nature.

[45]  William Ng,et al.  Frontal affinity chromatography with MS detection of EphB2 tyrosine kinase receptor. 2. Identification of small-molecule inhibitors via coupling with virtual screening. , 2005, Journal of medicinal chemistry.

[46]  Thomas Lengauer,et al.  Multiple-ligand-based virtual screening: methods and applications of the MTree approach. , 2005, Journal of medicinal chemistry.

[47]  Tudor I. Oprea,et al.  Integrating virtual screening in lead discovery. , 2004, Current opinion in chemical biology.

[48]  Yi Li,et al.  Analysis and optimization of structure-based virtual screening protocols. 2. Examination of docked ligand orientation sampling methodology: mapping a pharmacophore for success. , 2003, Journal of molecular graphics & modelling.

[49]  Andreas Evers,et al.  Virtual screening of biogenic amine-binding G-protein coupled receptors: comparative evaluation of protein- and ligand-based virtual screening protocols. , 2005, Journal of medicinal chemistry.

[50]  Paul D Lyne,et al.  Structure-based virtual screening: an overview. , 2002, Drug discovery today.

[51]  I. Lu,et al.  Structure-based drug design of a novel family of PPARgamma partial agonists: virtual screening, X-ray crystallography, and in vitro/in vivo biological activities. , 2006, Journal of medicinal chemistry.

[52]  Rick Mullin,et al.  PRIMING THE PIPELINE , 2004 .